Anjie Zheng

Title: Anjie Zheng: Innovator in Pharmaceutical Formulations

Introduction

Anjie Zheng is a notable inventor based in Hangzhou, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of injectable formulations for cancer treatment. His innovative work focuses on enhancing the solubility and efficacy of therapeutic agents.

Latest Patents

Anjie Zheng holds a patent for an all-trans retinoic acid injectant and its application. This patent describes an injectable formulation that includes all-trans retinoic acid and solubilizers. The formulation increases the apparent solubility of all-trans retinoic acid from 0.01 mg/mL to 0.1 mg/mL or more. This advancement allows for a reduction in the activity of immuno-suppressive cell populations within blood or tumor tissue, thereby improving immune responses against tumors. The injectable formulation can be used independently or in conjunction with other pharmaceutical products to inhibit tumor growth and prevent recurrence.

Career Highlights

Anjie Zheng is associated with Highfield Biopharmaceutical Corporation, where he continues to advance his research and development efforts. His work is pivotal in creating effective treatment options for cancer patients, showcasing his commitment to improving healthcare outcomes.

Collaborations

Anjie Zheng collaborates with esteemed colleagues, including Lieyi Wu and Xiaolong Chen. Their combined expertise contributes to the innovative projects at Highfield Biopharmaceutical Corporation.

Conclusion

Anjie Zheng's contributions to pharmaceutical innovations, particularly in cancer treatment, highlight his role as a leading inventor in the field. His patented formulations represent a significant step forward in enhancing therapeutic efficacy and patient care.